Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Watchful waiting: new study tracks rare tumor growth without immediate treatment

NCT ID NCT01801176

Knowledge-focused Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 100 adults with a rare, non-cancerous tumor called peripheral primitive fibromatosis. Instead of treating everyone right away, doctors monitored patients closely to see how the tumors behaved over three years. The goal was to learn which factors might predict tumor growth and to record what treatments were used if the tumor got worse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Jun 2012

Finished

Dec 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Peripheral primitive fibromatosis * Adults patients * Peripheral primitive fibromatosis proved by biopsy * Peripheral primitive fibromatosis R2 resected for which monitoring is decided * MRI realized before inclusion * Patient information and informed consent signed Exclusion Criteria: * Local recur * Head and neck topography * Primitive fibromatosis R0 or R1 resected * Specific medical treatment of fibromatosis * Patient already included in an other clinical trial with an experimental molecule * Persons deprived of liberty * Impossibility to submit to the trial's medical follow-up for psychological, geographical or socials reasons * Previous history of cancer * Counter indication to the realization of an MRI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Peripheral primitive fibromatosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fibromatosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Peripheral primitive fibromatosis

Contacts and locations

Locations

  • Institut Gustave Roussy

    Villejuif, Val de Marne, 94805, France